Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review

Overview

Journal Am J Trop Med Hyg

Specialty Tropical Medicine

Date 2018 Apr 12

PMID 29637880

Citations 24

Authors

Gyem Tshering

Palden Wangyel Dorji

Wanna Chaijaroenkul

Kesara Na-Bangchang

Affiliations

Soon will be listed here.

Abstract

Cholangiocarcinoma (CCA), a malignant tumor of the bile duct, is a major public health problem in many Southeast Asian countries, particularly Thailand. The slow progression makes it difficult for early diagnosis and most patients are detected in advanced stages. This study aimed to review all relevant articles related to the biomarkers for the diagnosis of CCA and point out potential biomarkers. A thorough search was performed in PubMed and ScienceDirect for CCA biomarker articles. Required data were extracted. A total of 46 articles that fulfilled the inclusion and had none of the exclusion criteria were included in the analysis (17, 22, 3, 4, and 1 articles on blood, tissue, bile, both blood and tissue, and urine biomarkers, respectively). Carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA), either alone or in combination with other biomarkers, are the most commonly studied biomarkers in the serum. Their sensitivity and specificity ranged from 47.2% to 98.2% and 89.7% to 100%, respectively. However, in the tissue, gene methylations and DNA-related markers were the most studied CCA biomarkers. Their sensitivity and specificity ranged from 58% to 87% and 98% to 100%, respectively. Some articles investigated biomarkers both in blood and tissues, particularly CA19-9 and CEA, with sensitivity and specificity ranging from 33% to 100% and 50% to 97.7%, respectively. Although quite a number of biomarkers with a potential role in the early detection of CCA have been established, it is difficult to single out any particular marker that could be used in the routine clinical settings.

Citing Articles

The Diagnostic and Prognostic Potentials of Non-Coding RNA in Cholangiocarcinoma.

Andrade R, Ribeiro I, Carreira I, Tralhao J Int J Mol Sci. 2024; 25(11).

PMID: 38892191 PMC: 11172565. DOI: 10.3390/ijms25116002.

Cholangiocarcinoma of the Common Bile Duct Presenting as Empyema of the Gallbladder: A Rare Case Report.

Khaladkar S, Jhala N, Dhande A, KirdatPatil P, M S Cureus. 2024; 16(5):e59865.

PMID: 38864065 PMC: 11166205. DOI: 10.7759/cureus.59865.

Practice guidelines for managing extrahepatic biliary tract cancers.

Kim H, Kang M, Kang J, Kim K, Kim B, Kim S Ann Hepatobiliary Pancreat Surg. 2024; 28(2):161-202.

PMID: 38679456 PMC: 11128785. DOI: 10.14701/ahbps.23-170.

Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.

Kikuchi Y, Shimada H, Yamasaki F, Yamashita T, Araki K, Horimoto K Int J Clin Oncol. 2024; 29(5):512-534.

PMID: 38493447 DOI: 10.1007/s10147-024-02497-0.

Fish and Food-Fatale: Food-borne Trematode and Cholangiocarcinoma.

Tan S, Machrumnizar M Helminthologia. 2024; 60(4):287-299.

PMID: 38222491 PMC: 10787637. DOI: 10.2478/helm-2023-0036.

References

Pinlaor S, Prakobwong S, Hiraku Y, Pinlaor P, Laothong U, Yongvanit P . Reduction of periductal fibrosis in liver fluke-infected hamsters after long-term curcumin treatment. Eur J Pharmacol. 2010; 638(1-3):134-41. DOI: 10.1016/j.ejphar.2010.04.018. View

Malesci A, Tommasini M, Bonato C, Bocchia P, Bersani M, Zerbi A . Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology. 1987; 92(1):60-7. DOI: 10.1016/0016-5085(87)90840-7. View

Tolek A, Wongkham C, Proungvitaya S, Silsirivanit A, Roytrakul S, Khuntikeo N . Serum α1β-glycoprotein and afamin ratio as potential diagnostic and prognostic markers in cholangiocarcinoma. Exp Biol Med (Maywood). 2012; 237(10):1142-9. DOI: 10.1258/ebm.2012.012215. View

Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81. DOI: 10.1056/NEJMoa0908721. View

Liu L, Wang J, Liu B, Dai S, Wang X, Chen J . Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma. J Cell Biochem. 2008; 104(3):745-55. DOI: 10.1002/jcb.21661. View

Chen L, Yan H, Yang W, Hu L, Yu L, Liu Q . The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol. 2008; 50(2):358-69. DOI: 10.1016/j.jhep.2008.09.015. View

Pattanapairoj S, Silsirivanit A, Muisuk K, Seubwai W, Chaon U, Vaeteewoottacharn K . Improve discrimination power of serum markers for diagnosis of cholangiocarcinoma using data mining-based approach. Clin Biochem. 2015; 48(10-11):668-73. DOI: 10.1016/j.clinbiochem.2015.03.022. View

Nischalke H, Schmitz V, Luda C, Aldenhoff K, Berger C, Feldmann G . Detection of IGF2BP3, HOXB7, and NEK2 mRNA expression in brush cytology specimens as a new diagnostic tool in patients with biliary strictures. PLoS One. 2012; 7(8):e42141. PMC: 3413695. DOI: 10.1371/journal.pone.0042141. View

Chainuvati T, Paosawadhi A, Sripranoth M, Manasatith S, VIRANUVATTI V . Carcinoma of the cystic duct associated with opisthorchiasis. Southeast Asian J Trop Med Public Health. 1976; 7(3):482-6. View

10.

Goonetilleke K, Siriwardena A . Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2006; 33(3):266-70. DOI: 10.1016/j.ejso.2006.10.004. View

11.

Todoroki T, Kawamoto T, Otsuka M, Koike N, Yoshida S, Takada Y . Benefits of combining radiotherapy with aggressive resection for stage IV gallbladder cancer. Hepatogastroenterology. 1999; 46(27):1585-91. View

12.

Tit-Oon P, Chokchaichamnankit D, Khongmanee A, Sawangareetrakul P, Svasti J, Srisomsap C . Comparative secretome analysis of cholangiocarcinoma cell line in three-dimensional culture. Int J Oncol. 2014; 45(5):2108-16. DOI: 10.3892/ijo.2014.2636. View

13.

Rucksaken R, Pairojkul C, Pinlaor P, Khuntikeo N, Roytrakul S, Selmi C . Plasma autoantibodies against heat shock protein 70, enolase 1 and ribonuclease/angiogenin inhibitor 1 as potential biomarkers for cholangiocarcinoma. PLoS One. 2014; 9(7):e103259. PMC: 4109983. DOI: 10.1371/journal.pone.0103259. View

14.

Boncinelli E . Homeobox genes and disease. Curr Opin Genet Dev. 1997; 7(3):331-7. DOI: 10.1016/s0959-437x(97)80146-3. View

15.

Khan S, Emadossadaty S, G Ladep N, Thomas H, Elliott P, Taylor-Robinson S . Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?. J Hepatol. 2011; 56(4):848-54. DOI: 10.1016/j.jhep.2011.11.015. View

16.

Matsuda A, Kuno A, Kawamoto T, Matsuzaki H, Irimura T, Ikehara Y . Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma. Hepatology. 2010; 52(1):174-82. DOI: 10.1002/hep.23654. View

17.

Bertram S, Padden J, Kalsch J, Ahrens M, Pott L, Canbay A . Novel immunohistochemical markers differentiate intrahepatic cholangiocarcinoma from benign bile duct lesions. J Clin Pathol. 2016; 69(7):619-26. DOI: 10.1136/jclinpath-2015-203418. View

18.

Srisomsap C, Sawangareetrakul P, Subhasitanont P, Panichakul T, Keeratichamroen S, Lirdprapamongkol K . Proteomic analysis of cholangiocarcinoma cell line. Proteomics. 2004; 4(4):1135-44. DOI: 10.1002/pmic.200300651. View

19.

Staab H, Anderer F, Brummendorf T, Hornung A, Fischer R . Prognostic value of preoperative serum CEA level compared to clinical staging: II. Stomach cancer. Br J Cancer. 1982; 45(5):718-27. PMC: 2011025. DOI: 10.1038/bjc.1982.113. View

20.

Jahng A, Chung D, Pham B, Reicher S, Yee B, Abramyan L . Staining for intracytoplasmic lumina and CAM5.2 increases the detection rate for bile duct cancers. Endoscopy. 2009; 41(11):965-70. DOI: 10.1055/s-0029-1215227. View